What is Vertex Pharmaceuticals's PP&E (net)?

Vertex Pharmaceuticals (VRTX) reported PP&E (net) of $1.52B in Q4 2025.

How has Vertex Pharmaceuticals's PP&E (net) changed year-over-year?

Vertex Pharmaceuticals's PP&E (net) increased by 23.8% year-over-year, from $1.23B to $1.52B.

What is the long-term trend for Vertex Pharmaceuticals's PP&E (net)?

Over 5 years (2020 to 2025), Vertex Pharmaceuticals's PP&E (net) has grown at a 9.7% compound annual growth rate (CAGR), from $958.5M to $1.52B.

What does PP&E (net) mean?

Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Vertex Pharmaceuticals VRTX PP&E (Net)

Discontinued — last reported Q4 '25

PP&E (Net) at other companies

Lexicon PharmaceuticalsLXRX

$1.75M-24.0%

Travere Therapeutics, Inc.TVTX

$3.63M-25.3%

Agios PharmaceuticalsAGIO

$10.57M-4.5%

AbbVieABBV

$5.69B+8.6%

4D Molecular TherapeuticsFDMT

$13.59M-27.5%

Beam TherapeuticsBEAM

$101.25M-7.6%

Segments

By geography

See full

United States$2.39B—

United Kingdom$176.6M—

Other financials

Income statement

See full

Revenue$3.0B+7.8%

Gross profit$2.6B+7.8%

Operating income$1.1B+80.6%

Net income$1.0B+59.6%

EPS (diluted)$4.02+61.4%

Balance sheet

See full

Cash & equivalents$5.5B+17.5%

Total debt$2.0B+20.5%

Total equity$19.4B+17.4%

Total assets$26.5B+15.8%

Cash flow

See full

Operating cash flow$1.4B+74.4%

CapEx$133.4M+228%

Free cash flow$1.3B+66.4%

Valuation

See full

Market cap$121.87B+7.6%

Enterprise value$118.35B+7.4%

P/E28.1×—

P/S10×-0.2×

Profitability

See full

Gross margin86.2%+0.2pp

Operating margin38.3%—

Net margin35.5%—

FCF margin30.4%+20.2pp

Returns & leverage

See full

Return on equity24.2%—

Debt / equity0.1×0.0×

Current ratio3×+0.4×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization.

The official record: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vertex Pharmaceuticals's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vertex Pharmaceuticals's PP&E (net)?: Vertex Pharmaceuticals (VRTX) reported PP&E (net) of $1.52B in Q4 2025.
How has Vertex Pharmaceuticals's PP&E (net) changed year-over-year?: Vertex Pharmaceuticals's PP&E (net) increased by 23.8% year-over-year, from $1.23B to $1.52B.
What is the long-term trend for Vertex Pharmaceuticals's PP&E (net)?: Over 5 years (2020 to 2025), Vertex Pharmaceuticals's PP&E (net) has grown at a 9.7% compound annual growth rate (CAGR), from $958.5M to $1.52B.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.